POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.
Did Not Advance

Wisconsin bill extends prescription drug monitoring requirements and board reviews to 2030

Original title: An Act to amend 961.385 (2) (cs) 1., 961.385 (5) (b) and 961.385 (6) (a) of the statutes; Relating to: the prescription drug monitoring program. (FE)

Last action · March 23, 2026: Failed to pass pursuant to Senate Joint Resolution 1Sponsors: Barbara Dittrich and 1 other

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Proposed

Wisconsin Assembly Bill 68 extends two expiring provisions related to the state's by five years to 2030: the requirement for practitioners to review patient records before issuing a prescription, and the requirement for the Controlled Substances Board to conduct quarterly outcome reviews.

Why it matters

Extends mandatory patient record checks by medical practitioners and state oversight evaluations until 2030, affecting prescribers, pharmacists, and patients involved in controlled substance treatments.

Who It Would Have Affected

Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.

Directly affected

health care practitioners

Practitioners must continue reviewing patient records in the prescription drug monitoring program before issuing prescription orders until April 1, 2030.

Directly affected

Controlled Substances Board

The board is required to continue conducting and reporting quarterly reviews of the program's outcomes until October 30, 2030.

Directly affected

patients

Patients seeking controlled substance prescriptions remain subject to mandatory record checks by their practitioners through 2030.

Key Facts

  • Extends the requirement for health care practitioners or their agents to review patient records before issuing a prescription order from April 1, 2025, to April 1, 2030.
  • Extends the Controlled Substances Board's requirement to conduct quarterly reviews evaluating actual versus projected outcomes of the prescription drug monitoring program from October 30, 2025, to October 30, 2030.
  • Extends the requirement to publish or report the results of the board's quarterly reviews from October 30, 2025, to October 30, 2030.

Frequently Asked Questions

What does Assembly Bill 68 change about the prescription drug monitoring program?
It extends the expiration dates for two major components of the program—mandatory patient record reviews by practitioners and quarterly board evaluations—by five years to 2030.
Who must review patient records before issuing a prescription under these rules?
Health care practitioners or their designated agents, in accordance with applicable standards of practice.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

This bill did not become law - Failed in the Assembly.

Procedural history

13 actions
  1. Mar 23, 2026House
    Failed to pass pursuant to Senate Joint Resolution 1
  2. Mar 20, 2025House
    Laid on the table
  3. Mar 18, 2025House
    Placed on calendar 3-20-2025 by Committee on Rules
  4. Mar 13, 2025HouseCommittee
    Referred to committee on Rules
  5. Mar 13, 2025HouseFloor
    Report passage recommended by Committee on Health, Aging and Long-Term Care, Ayes 15, Noes 0
  6. Mar 13, 2025House
    Executive action taken
Show 7 earlier actions
  1. Mar 12, 2025House
    Representative Moore Omokunde added as a coauthor
  2. Mar 12, 2025House
    Public hearing held
  3. Mar 11, 2025House
    Representative Stubbs added as a coauthor
  4. Mar 4, 2025House
    Representative Subeck added as a coauthor
  5. Feb 26, 2025House
    Fiscal estimate received
  6. Feb 24, 2025HouseIntroduced
    Read first time and referred to Committee on Health, Aging and Long-Term Care
  7. Feb 24, 2025HouseIntroduced
    Introduced by Representative Dittrich; cosponsored by Senator Testin

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

TestinAssemblyPrimary sponsorNo profile match

Connected Entities

Controlled Substances Board
OrganizationControlled Substances Board“Required to establish and conduct reviews of the prescription drug monitoring pr”Map →

Sources

Open source document

docs.legis.wisconsin.gov

Analysis Score

0–100
  • Significance20
    Lowered because this bill did not pass (its text scored 45)
  • Controversy15
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz10
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record